HUMALOG MIX 50/50 PEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HUMALOG MIX 50/50 PEN (HUMALOG MIX 50/50 PEN).
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on liver, muscle, and adipose tissue, promoting glucose uptake and storage, and inhibiting hepatic glucose production.
| Metabolism | Insulin lispro is metabolized by insulin-degrading enzyme (IDE); the exact hepatic and renal catabolic pathways are similar to human insulin. |
| Excretion | Renal: 75-80% as metabolites; hepatic: 20-25% via biliary elimination. |
| Half-life | Terminal half-life: 0.5-1.0 hour (insulin lispro); clinical context: short duration due to rapid clearance. |
| Protein binding | Protein binding: <10% (albumin); clinical relevance minimal. |
| Volume of Distribution | Volume of distribution: 0.26-0.35 L/kg; indicates distribution into extracellular fluid. |
| Bioavailability | Subcutaneous: 55-75% (relative to intravenous); absolute bioavailability ~60%. |
| Onset of Action | Subcutaneous: 15-30 minutes; intravenous: immediate. |
| Duration of Action | Subcutaneous: 12-18 hours (overall due to NPL component); peak effect 1-6 hours; clinical note: longer duration from protamine suspension. |
Subcutaneous injection, 0.5 to 1 unit/kg/day divided into two doses (before breakfast and before dinner), individualized based on blood glucose levels.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment recommended; monitor blood glucose closely as renal impairment may increase risk of hypoglycemia. GFR < 30 mL/min: consider dose reduction and increased monitoring. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B or C: start with lower doses and titrate cautiously due to impaired gluconeogenesis and altered insulin clearance. |
| Pediatric use | Weight-based: 0.25 to 1 unit/kg/day divided into two doses for children >2 years; titrate based on blood glucose. Not recommended for children <2 years due to lack of data. |
| Geriatric use | Start with lower doses (e.g., 0.2–0.4 unit/kg/day) to minimize hypoglycemia risk; titrate slowly with careful glucose monitoring. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HUMALOG MIX 50/50 PEN (HUMALOG MIX 50/50 PEN).
| Breastfeeding | Insulin lispro is excreted into breast milk in negligible amounts; M/P ratio not established. It is considered compatible with breastfeeding. Maternal insulin requirements may decrease postpartum. |
| Teratogenic Risk | Insulin lispro does not cross the placenta in significant amounts. No increased risk of major birth defects or miscarriage has been observed with insulin lispro use during pregnancy. Poor glycemic control during the first trimester is associated with an increased risk of congenital anomalies; during the second and third trimesters, it increases the risk of macrosomia, polyhydramnios, and preterm labor. |
■ FDA Black Box Warning
None (Humalog Mix 50/50 does not have a black box warning; however, all insulins carry a risk of severe hypoglycemia).
| Serious Effects |
["Hypersensitivity to insulin lispro or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia: Most common adverse effect; may be severe and life-threatening. Monitor blood glucose closely, especially with dose changes or missed meals.","Hypersensitivity reactions: Allergic reactions to insulin or excipients may occur. Discontinue if anaphylaxis or severe allergy develops.","Injection site reactions: Lipodystrophy, hypertrophy, or local allergic reactions; rotate injection sites.","Hypokalemia: Insulin can cause potassium shift from extracellular to intracellular space; use caution in patients at risk for hypokalemia.","Mixing with other insulins: Do not mix with other insulins in same syringe; only compatible with certain intravenous admixtures under controlled conditions.","Hyperglycemia due to pump failure: Not for use in insulin pumps; may cause rapid hyperglycemia."] |
Loading safety data…
| Fetal Monitoring | Monitor blood glucose levels frequently; hemoglobin A1c each trimester; fetal ultrasound for growth and anatomy; maternal blood pressure and renal function; fetal monitoring for macrosomia. |
| Fertility Effects | Uncontrolled diabetes can impair fertility due to menstrual irregularities and ovulatory dysfunction. Insulin lispro itself is not known to adversely affect fertility. |